A cute pancreatitis (AP) was the third most common gastrointestinal diagnosis in 2012, resulting in approximately 275,000 admissions and costing about $2.6 billion. 1, 2 It is also the most common pancreatic disease worldwide. 3 The incidence is increasing, but death rates have actually decreased in recent years to <2%. 1 However, !50% of the deaths occur within the first 2 weeks of diagnosis. 4, 5 The recent revised Atlanta classification 6 described mild (usually interstitial), moderately severe (local complications without persistent organ failure), and severe (persistent organ failure) AP subtypes. Necrotizing pancreatitis is defined by the presence of pancreatic and/or peripancreatic necrosis and is usually associated with moderately severe or severe subtypes. Mild or interstitial AP is the most common type observed in 75%À80% of all patients. A fourth class of severity, critical AP, is described in the determinant-based classification 7 when both infected necrosis and persistent organ failure are present together.
AP has 2 phases, each with hallmark clinical features. The early phase spans the first 1À2 weeks and the late phase begins at 2 weeks and beyond. Whereas the systemic inflammatory response syndrome (SIRS) and the resultant organ failure dominate the early phase, the late phase is characterized by local complications of necrosis and pancreatic fluid collections, including infection, which is much more common in the late phase. 6 To date, there is no drug available to treat AP, so most care is supportive. With this limitation, most clinical management guidelines 8, 9 emphasize an approach that includes predicting and establishing the severity of AP to triage patients to appropriate levels of care; administering supportive care, including intravenous hydration and enteral nutrition; and treating the underlying cause and complications by appropriate use of urgent endoscopic retrograde cholangiopancreatography (ERCP), early cholecystectomy, targeted use of antibiotics, and interventions for pancreatic fluid collections in the later stages, usually after 4 weeks.
There is general agreement that the "initial period" of AP refers to the first 72 hours after diagnosis (the median length of stay for all patients is 3 days). 1 Key management in this phase includes identifying the cause, predicting the severity, intravenous hydration, and urgent ERCP (if indicated). Other treatment decisions, for example, enteral nutrition, early cholecystectomy, and alcohol counseling before hospital discharge, may take place beyond the first 72 hours, which might support extending the "initial period" of management up to 7 days after diagnosis. For the purpose of this technical review, the initial period encompasses the first 7 days, although most of the discussion pertains to the initial 72 hours. This review does not address imaging because it is not necessary to obtain a computed tomography scan early on if 2 criteria (typical pain and !3-fold elevation of pancreatic enzymes) are present. Also the need for magnetic resonance imaging, endoscopic ultrasound, and repeat computed tomography scan, if one is performed initially, are all beyond the scope of this review.
There is unanimity about routine use of abdominal ultrasound to detect gallstones and sludge (observed in approximately 30%À40% of all cases of AP). 8, 9 Despite several observational and randomized trials, and an abundance of guidelines, systematic reviews, and meta analyses, many management decisions in AP are far from clear, including the optimal method of intravenous hydration; ideal predictor of severity; timing of oral feeding; type of initial oral food; indication, timing, and method of enteral nutrition; role of prophylactic antibiotics; role of urgent ERCP; timing of cholecystectomy in biliary AP; and interventions before admission for alcohol cessation for alcoholic AP.
This led the American Gastroenterological Association (AGA) Institute to undertake a technical review of the initial medical treatments for AP, specifically those that impact outcomes. 10 The main purpose is to critically review studies using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and to generate summary evidence and estimates for the guidelines panel to develop evidence-based recommendations.
Methods

Overview
This review collects and evaluates pertinent literature concerning the acute early management (first 72 hours, up to 7 days for certain treatments) of patients presenting with AP, focusing on therapeutic interventions that impact outcomes. With these data, the AGA's Medical Position Panel will, in turn, produce the final set of recommendations, as described previously. 10 Methods for deriving focused clinical questions, systematically reviewing and rating the quality of evidence for each outcome, and rating the overall quality of evidence were based on the GRADE framework, which have been described in detail elsewhere, [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and are more specifically reported here. The PICO format frames a clinical question by defining a specific patient population (P), intervention (I), comparator (C), and outcome(s).
Formulation of Clinical Questions
The participants included SSV, CEF, MJD, and ANB as selected by the AGA Clinical Guidelines Committee based upon clinical content and guidelines methodologic expertise. Focused questions were generated, and for each question a statement was framed in terms of a respective PICO. 25 In accordance with a modified Delphi method, the questions and PICO statements were developed by multiple structured iterations until a consensus among experts was reached. 26, 27 The final proposed clinically pertinent list of topics addressed focused on questions and PICO statements related to the early management of patients presenting with AP. The AGA Governing Board approved the final set of questions. The final PICO statements are shown in Supplementary Table 1.
Search Strategy
An experienced librarian conducted distinct computer medical literature searches using the following databases until February 2016: Medline, Embase, Cochrane, and Health Technology Assessment. All searches included a highly sensitive search strategy to identify reports of randomized trials with a combination of controlled vocabulary and text words; the patient population targeted was those presenting with AP. With regard to interventions, the first search performed for PICO question 1 included the terms related to aggressive hydration. PICO question 2 included terms related to antibiotic prophylaxis. PICO question 3 included terms for ERCP, biliary tract diseases, and gallstones. The searches for PICO questions 4, 5, and 6 were combined and included terms related to nutrition support, artificial feeding, and dietary supplements or type. PICO question 7 included terms related to cholecystectomy. PICO question 8 included terms related to alcohol-related disorders or counseling (complete search strings are shown in Supplementary Table 2 ). The search for PICO question 9 were related to disease severity or scoring systems. In addition, recursive searches and cross-referencing were performed, and hand searches of articles identified after the initial search were also completed.
Trial Selection and Patient Population
Only fully randomized controlled trials (RCTs) published in English during the prespecified time periods were included (see search strings, Supplementary Table 2) . Studies comprising pediatric populations, as well as Letters, Notes, Case Reports, or Comments, and any trials published in languages other than English were excluded.
Choice of Outcomes
Lists of prespecified critical and important outcomes were identified a priori. Although most were common to all PICOs, certain additionally clinically relevant outcomes pertinent to some questions were also specified. Death, single or multiple persistent organ failure (>48 hours), and infected pancreatic and/or peripancreatic necrosis are the clinical outcomes of importance in AP. 28 Hospital stay, need for and length of intensive care unit stay, and need for interventions are surrogate markers for the important clinical outcomes mentioned here, 29 but are commonly reported in most of the studies along with transient organ failure, which does not qualify to make the diagnosis of severe acute pancreatitis (SAP). A list of all outcomes with their respective ordinal ranking is shown in Supplementary Table 3 . Blank cells indicate an outcome that was sought but not reported in selected studies.
Validity Assessment
Three investigators (SSV, CEF, and MJD) evaluated study eligibility independently, with discrepancies resolved after discussion and reaching a consensus. Data extraction was thoroughly performed by content experts (SSV, CEF, and MJD). Risk of bias for individual studies was assessed using the Cochrane Risk of Bias Tool. The quality of the evidence for each outcome and overall for each PICO was rated as very low, low, moderate, or high, based on the GRADE methodology 30 ; disagreements were resolved by discussion. Quality of evidence definitions are available elsewhere. 30 
Statistical Methods
For each outcome and in every comparison, effect size was calculated as odds ratios (ORs) for categorical variables and weighted mean differences (WMDs) for continuous variables, where applicable. The DerSimonian and Laird method 31 for random effect models was applied to determine corresponding overall effect sizes and their confidence intervals (CIs), as the population was thought to include heterogeneous population or methods across the included trials. WMDs were handled as continuous variables using the inverse variance approach. The presence of statistical heterogeneity across studies was defined using a c 2 test of homogeneity with a 0.10 significance level. The Higgins I 2 statistic was calculated to quantify the proportion of variation in treatment effects attributable to between-study heterogeneity 32 ; values of 25%, 50%, and 75% represent low, moderate, and high heterogeneity, respectively.
Values for intention-to-treat were preferred to per protocol when both were presented. Depending on what data were available or could be reconstructed, in order to minimize bias, we included noncompliant patients or withdrawals in the intention-to-treat analysis. 33 For all comparisons, publication bias was evaluated using funnel plot asymmetry 34 (data available upon request). All percentages of outcomes reported in the trials were converted to absolute numbers and no attempt at determining extractable values from graphics or figures was made to avoid any subjective interpretation. All statistical analyses were completed using Review Manager (RevMan), version 5.3 (The Nordic Cochrane Centre, the Cochrane Collaboration, 2014) and Meta package in R version 2.13.0 (R Foundation for Statistical Computing, Vienna, Austria, 2008).
Presentation of Results
We present each focused question related to one of the PICO statements and the grading of the evidence for each component of the statement. After pertinent background information, the quantitative results are then presented along with pertinent narrative information to provide explanatory context for the results; the evidence base reports detail the rationale for the grading of quality of evidence. Suggested future research is also identified. Related PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagrams are presented in Supplementary Material 4 and Cochrane Risk of bias tool assessments in Supplementary Material 5. Related Forest plots are available upon request.
Results
Question 1: What is the Role of Intravenous Hydration in the Initial Management of Patients With Acute Pancreatitis?
Effect of fluid resuscitation on the outcomes of mortality, infected pancreatic necrosis, persistent multiple organ failure (PMOF), persistent single organ failure (PSOF), multiple organ failure (MOF) of unclear duration, single organ failure (unclear duration) and hospital length of stay (LOS).
Quality of evidence: Very low Background information. Many different hydration solutions and methods of administration have been studied in the initial management of AP. Hypovolemia in AP can occur for many reasons, including third-space fluid loss. 35 Hypovolemia contributes to renal and circulatory failure and also can lead to or exacerbate a microcirculatory defect in the pancreas, resulting in worse pancreatic and peripancreatic necrosis. 36 Thus, the rationale of fluid therapy in the initial management of AP has been emphasized in all guidelines to prevent these consequences. Although limited in number, randomized trials have assessed the role of crystalloid solutions, colloid expanders, and, more recently, goal-directed therapy. The various aims and metrics of goaldirected therapy include heart rate, blood pressure, mean arterial pressure, urine output, hematocrit, blood urea nitrogen (BUN), creatinine, central venous pressure, stroke volume variation, and intrathoracic blood volume. Whereas goal-directed therapy had a specific definition when it was developed for treatment of sepsis, 37 it has also been studied in a breadth of conditions using heterogeneous goals and protocols, such that a recent systematic review 38 found scant high-quality evidence for the numerous goal/method combinations. In AP, 3 guidelines are instructive. Recommendations were weak 8 or strong 9, 39 for lactated Ringer's solution as the preferred type of fluid, with different rates and levels of evidence: 5À10 mL/kg/h 9 (moderate quality evidence), 250À500 mL/h during the first 12À24 hours using frequent clinical assessments to decrease BUN 8 (moderate quality evidence), and 150À600 mL/h 39 (lowquality evidence). One guideline 9 also made weak recommendations for goal-directed therapy using clinical, biochemical, and invasive targets (moderate quality evidence). As a more sobering appraisal of the literature, the systematic review by Haydock et al 35 analyzed 15 studies (including 4 RCTs) and concluded that fluid therapy is considered a cornerstone of the early management of patients with AP and yet the evidence on which it is based remains "paltry and of poor quality."
Results from the current systematic review. From an initial 382 citations, 7 RCTs addressed different solutions or methods of administering intravenous fluids in the initial management of AP; experimental interventions in some studies were also considered a control fluid administration in others. These publications also report different outcomes in varying populations of patients with AP ( 40 assessed nasojejunal (NJ) goal-directed therapy compared to intravenous goal-directed therapy, but the data could not be analyzed with these studies because it compared 2 different goal-directed therapies. None of the reported critical outcomes differed between groups in this trial (Table 2) .
While lactated Ringer's has the theoretical benefit of decreasing pancreatic acidosis and reducing trypsin activity, and has been shown to improve outcomes like C-reactive protein (CRP) levels and SIRS in some trials, treatment allocation and choice of outcomes did not allow for a determination of the impact of lactated Ringer's administration for any of the chosen critical or important outcomes.
In the 2 trials (n ¼ 161) that examined the administration of 6% hydroxyethyl starch (HES, a non-ionic starch derivative used as a volume expander) compared to fluids without 6% HES, mortality was not significantly different (2 trials; OR, 0.47; 95% CI, 0.15À1.51). Rates of infected pancreatic necrosis, PMOF, and PSOF were not reported in the included trials. MOF was significantly increased (OR, 3.86; 95% CI, 1.24À12.04) with 6% HES administration in 1 trial 41 (Table 3 ). An important limitation of this analysis is that most of the studies did not distinguish between transient and persistent organ failure because many predated the prognostically important new definition of persistent organ failure. 6 Hence, the single and multiple organ failure diagnoses in these studies included both transient and persistent types. The interpretation of these results is further limited by a serious risk of bias in many trials, the small number of studies, wide uncertainty around efficacy point estimates as reflected by broad CIs, and lack of consistency in outcome findings across different trials.
Even more pronounced methodologic limitations apply to the results addressing some of the a prioriÀdefined Goal-directed critical outcomes, with even fewer studies including extractable data for these ( Table 1) . As an example, the study by Wu et al 42 showed improved outcomes attributable to the use of a lactated Ringer's solution vs normal saline (for goal-directed and standard volume administration protocols grouped together for each fluid type) but only with regard to the incidence of SIRS after 24 hours (84% reduction vs 0%, respectively; P ¼ .035), and reduced CRP levels (51.5 vs 104 mg/dL, respectively; P ¼ .02).
In conclusion, there is insufficient evidence to state that goal-directed therapy, utilizing various parameters to guide fluid administration, reduces the risk of persistent single or multiple organ system failure, infected (peri) pancreatic necrosis or mortality from AP. There is also no RCT evidence that any particular type of fluid therapy (eg, lactated Ringer's) reduces the risk of mortality or persistent single or multiple organ failure. The addition of HES to usual intravenous fluids does not reduce the risk of mortality, and may increase the risk of persistent multiple organ system failure in AP.
Recommendations for future clinical trials on the topic. We would suggest that intravenous hydration in AP include the following goals: (1) enroll consecutive patients (because there is no reliable method at the present time to predict moderately severe or severe types); (2) prioritize the measurement of critical outcomes outlined in this systematic review; (3) and attempt to address important but unanswered questions, including the role of goal-directed therapy and the type of goal-directed therapy, the type of fluid to be used (lactated Ringer's, saline, synthetic colloids), as well as the volume and rate of fluid therapy, and its timing of administration as well as duration.
Question 2: What Is the Role of Prophylactic Antibiotics in Predicted Severe Acute Pancreatitis and Necrotizing Acute Pancreatitis?
Effect of prophylactic antibiotics on the outcomes of mortality, infected pancreatic necrosis, PMOF, PSOF, MOF, or multiple organ dysfunction of unclear duration, single organ failure of unclear duration, and hospital LOS.
Quality of evidence: Low Background information. Infections in AP (pancreatic and extrapancreatic) are common and result in significant morbidity and mortality. While the original Atlanta classification 43 defined several local pancreatic complications (pseudocyst, necrosis, or abscess), which were classified as SAP, the revised Atlanta classification defined local complications as acute collections (acute peripancreatic and pancreatic fluid collections, acute necrotic collections) or mature collections (pseudocyst and walled-off necrosis), which were classified as moderately severe AP or SAP, respectively, depending on the absence or presence of persistent organ failure. 6 Necrotizing pancreatitis includes both peripancreatic and pancreatic necrotic collections, which mature into collections of walled-off necrosis, usually after 4 weeks. Infected necrosis is infection of (peri) pancreatic necrosis, and is associated with high mortality (in the range of 30%). 8 According to a recent systematic review, mortality doubles when (peri) pancreatic necrosis becomes infected in patients with coexisting organ failure. 44 Reducing infected necrosis, morbidity, and mortality is the rationale for administering prophylactic antibiotics (before a documented infection) to patients with either predicted SAP (which is associated with a higher risk of developing necrotizing pancreatitis) or those with established necrotizing pancreatitis. The antibiotics used in most of the AP trials were capable of penetrating the infected necrosis, for example, fluoroquinolones, metronidazole, carbapenems, and third-generation cephalosporins. Whereas earlier trials and meta-analyses often showed that prophylactic antibiotics improved certain outcomes (eg, mortality and infectious complications), more recent studies and meta-analyses have often failed to confirm such benefit, likely due to higher-quality methodology over time. 45, 46 Inherent methodologic problems described by earlier reviews and recent meta-analysis are most pronounced among older studies and include differences in inclusion criteria, variable prophylactic antibiotic treatment regimens, inconsistent double blinding, and use of non-placebo controlled study design that compares 2 antibiotics. Hence, recent guidelines do not recommend prophylactic antibiotics to prevent infection in sterile necrosis in AP. 8, 9 A persistent concern in the field is that methodologic problems across trials might mask detection of an important clinical benefit of prophylactic antibiotics, perhaps in certain subgroups with extensive necrosis 47 and persistent organ failure (usually known only after 48 hours).
Results of the current systematic review. From 263 citations, we identified 10 RCTs (n ¼ 701) that addressed the role of prophylactic antibiotic coverage (Table 4) . Mortality exhibited a trend toward reduction with the prophylactic use of antibiotics (OR, 0.66; 95% CI, 0.42À1.04) that disappeared in subgroup analysis among more recent studies (after 2002: OR, 0.85; 95% CI, 0.52À1.80) ( Table 5) . Infected peripancreatic necrosis, was significantly lowered with antibiotic prophylaxis (OR, 0.56; 95% CI, 0.36À0.86), but no difference in this outcome was noted among more recent trials (OR, 0.81; 95% CI, 0.44À1.49) (Table 5) . Similarly, no between-group differences in mortality or peripancreatic necrosis were noted among higher-quality trials (data available upon request). Persistent single organ failure was not reduced by prophylaxis antibiotics (OR, 0.19; 95% CI, 0.01À4.06). No studies reported on the outcome of PMOF. None of the additional important outcomes were significantly improved with prophylactic antibiotic administration, including MOF or multiple organ dysfunction of unclear duration, single organ failure of unclear duration, and hospital LOS ( Table 5 ).
The absence of significant findings among more recent and better-quality trials is likely attributable to the methodologic limitations mentioned, more prominently noted among older trials.
Several trials related to the focus of this AGA technical review were of interest but were excluded because the nature of the intervention was not sufficiently comparable to prophylactic intravenous antibiotic treatment trials included in the review, namely intra-arterial administration of both antibiotics and protease inhibitors 9, 10 and selective decontamination of the gut.
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Recommendations for future clinical trials on this topic. Future studies should adopt a rigorously adequately powered multicenter trial design to uncover any possible benefits not shown previously due to small sample size. Future studies should also clarify whether specific subgroups may benefit from prophylactic antibiotics, including those with predicted SAP or both extensive sterile necrosis and persistent organ failure, and whether treatment with gut decontamination improves outcomes in patients with predicted SAP (and possibly other subgroups). Effect of urgent ERCP on the outcomes of mortality, PMOF, PSOF, MOF of unclear duration, single organ failure of unclear duration, infected (peri) pancreatic necrosis, total infected pancreatic necrosis and hospital LOS.
Quality of evidence: Low. Background information. Gallstones and alcohol are the most common causes of AP. The presumed mechanism by which gallstones cause AP is the temporary obstruction of the ampulla of Vater by a stone, resulting in increased intra-pancreatic duct pressure and subsequent activation of pancreatic digestive enzymes. After triggering AP, most gallstones pass through the ampulla into the duodenum. Therapeutic ERCP emerged in the 1970s as an urgent/ emergent biliary drainage procedure in patients with gallstone AP complicated by persistent choledocholithiasis and biliary obstruction, particularly those with acute cholangitis. Treatment typically includes biliary sphincterotomy followed by extraction of biliary stones. Several RCTs and meta-analyses partially defined the role of urgent ERCP in biliary AP, identifying advantages in some clinical outcomes and contexts but uncertain benefits in others. 48, 49 According to 2 recent guidelines, urgent ERCP in biliary AP is indicated when the disease (mild or severe) is complicated by cholangitis, 8, 9 is reasonable for persistent biliary obstruction without cholangitis, 9 and is not indicated in the absence of cholangitis or persistent biliary obstruction. Finally, in the absence of cholangitis, the role and timing (<24 hours, <48 hours, or <72 hours) of "therapeutic" ERCP remain unclear in predicted severe biliary AP with persistent biliary obstruction.
As urgent ERCP is indicated and the treatment of choice for acute cholangitis, [50] [51] [52] patients with definite AP are generally (especially in more recent trials) excluded from RCTs of urgent ERCP in the setting of acute biliary pancreatitis, yet differentiating cholangitis from persistent biliary obstruction may not always be clinically straightforward. The diagnosis of acute cholangitis is reasonably certain in the presence of Charcot's triad (right upper quadrant abdominal pain, jaundice, and fever) plus leukocytosis, but Figure 4a , 4b, and Table 6 ). Mortality, MOF, single organ failure (respiratory, renal, circulatory), infected (peri) pancreatic necrosis, and total necrotizing pancreatitis were no different between patients randomized to the urgent ERCP or the conservative management groups; subgroup analyses that assessed all studies and those having excluded patients with biliary obstruction showed similar findings. In addition, no differences were attributed to EPCP among patients with pancreatitis and cholangitis, although the outcome was reported in small numbers of patients and in only 1 trial. 54 The only significant difference in outcomes pertained to LOS that was significantly decreased with urgent ERCP WMD ¼ À8.8 (95% CI, À12.64 to À4.96) (1 trial, n ¼ 120 patients).
Although most of the recent trials specifically attempted to exclude patients with suspected cholangitis, there remains marked clinical heterogeneity in adopted selection criteria/definitions limiting the interpretation of the findings (Table 7) .
Recommendations for future clinical trials on the topic. Future trials should adopt strict inclusion and exclusion criteria, and definitions for persistent biliary obstruction, cholangitis, and predicted severe biliary AP. These studies should be adequately powered to permit meaningful analysis of all 3 of the latter patient subgroups. The timing of the ERCP intervention should be 24À48 hours after diagnosis (24 hours to allow spontaneous passage of stone and 48 hours to ensure that prolonged biliary obstruction does not occur).
Questions 4, 5, 6: Nutritional Interventions in Acute Pancreatitis
Nutrition and feeding of patients with AP is a broad, complex, and evolving topic. RCTs have compared nil per os (npo) to oral feeding, enteral nutrition to total parenteral nutrition (TPN), types of oral feeding (liquid vs soft vs solid; and escalating vs full diet from the beginning), the timing of oral and enteral tube feeding (early vs delayed), enteral feeding to TPN, and nasogastric (NG) to NJ feeding. Among these comparisons, 3 critical questions (PICO questions 4, 5, and 6) are germane to the management of most patients with AP. It must be recognized, in light of the adopted timelines of interest in medical management for this technical review, that the timing of decisions to initiate feeding may occur within the first 24À48 hours, but may also extend beyond the first 24À48 hours in more severe cases. PICO questions 4, 5, and 6 are inter-related. To avoid redundancy we consolidated the background information for each as 1 section and present it under PICO question 4.
Question 4: What Is the Benefit of Early Feeding in Mild or Severe Pancreatitis?
Effect of early oral feeding on mortality, PMOF, and PSOF, MOF of unclear duration, single organ failure of unclear duration, and infected (peri) pancreatic necrosis, as well as total infected pancreatic necrosis and hospital LOS.
Quality of evidence: Moderate Background information. Historically, the focus of nutrition and feeding during AP aimed to "rest the pancreas," mainly by providing npo, and removing the foodinduced stimulation of exocrine pancreatic secretion, which presumably reduces enzyme-driven inflammation and promotes earlier recovery, and/or to address intolerance to feeding by mouth, namely by fasting or by administering TPN. More recently, the focus has shifted toward protecting the gutÀmucosal barrier by initiating enteral feeding, either orally or by enteral tube. Overall, this approach to patients with AP has mirrored decisions to "resting the gut" during management of other acute abdominal conditions. From a practical standpoint, feeding by mouth is sometimes not feasible in patients with AP (or acute abdominal conditions) who have significant nausea and vomiting (often associated with a paralytic ileus).
TPN was initially recommended to prolong "resting of the pancreas" while avoiding adverse effects of malnutrition associated with fasting. Despite this theoretical advantage, it became apparent that most patients with mild or interstitial AP recover in a very short time and do not require TPN. As a result, administering TPN was restricted to patients with predicted severe or proven necrotizing AP. Clinical use of TPN declined further with accumulation of evidence that enteral feeding had a beneficial trophic effect on the gutÀmucosal barrier, thereby reducing bacterial translocation from the lumen into the bloodstream and reducing the risks of infection of (peri) pancreatic necrosis (infected necrosis) and severe outcomes in necrotizing AP. Thus the concept of "gut rousing not gut resting" was introduced. 55 Recent guidelines have recommended early oral feeding in mild (interstitial) AP. 8, 9 In patients with predicted severe or necrotizing AP, hospital stay is typically prolonged and patients are often intolerant to oral feeding. In these latter groups of patients, establishing a definite diagnosis of severe or necrotizing AP usually occurs between 3 and 5 days after initial presentation, a time when NG or NJ feeding was recommended to maintain the gutÀmucosal barrier and to prevent infected necrosis. Randomized clinical trials and meta-analyses 56 have demonstrated the superiority of enteral nutrition over TPN with regard to reducing complications (mainly infectious), cost and mortality in predicted severe, and necrotizing types of AP, and rarely in mild AP. A more recent systematic review suggested early oral or enteral tube feeding (within 48 hours) was not associated with any adverse effects in mild to moderate or predicted SAP, and may even reduce LOS in mild to moderate AP. 57 Few studies have compared NG feeding to NJ (nasoduodenal in some) feeding in predicted severe or necrotizing AP 58 because NG tubes can be placed at the bedside, making it simple and cheap. No differences between the 2 routes of feeding have been noted, although many methodologic problems with these studies preclude a definitive conclusion. 59 To investigate the physiologic benefits attributable to distal duodenal compared to NG feeding, a large multicenter study compared NG to NJ feeding in AP, unfortunately, the trial (ClinicalTrials.gov NCT00580749) was terminated early due to difficulties recruiting patients.
Results from the current systematic review
From 547 citations, we identified 15 RCTs that addressed the role of early vs delayed feeding ( Table 8) . Four of the 15 were not included in the analyses because timing of feeding was not clearly identified. Mortality was not significantly different for delayed compared to early feeding (OR, 0.59; 95% CI, 0.22À1.59) or any of the other noted outcomes. There exists some clinical heterogeneity in the time to feeding that extends beyond the scope of the first 48 hours targeted by this technical review, varying in part according to the severity of the AP as discussed, but this was not believed to significantly invalidate the results. Subgroup analyses showed no differences in outcomes when comparing npo vs early oral feeding or enteral feeding (data available upon request). However, in the comparison of npo vs early enteral feeding, the rate of intervention for necrosis was increased (OR, 2.47; 95% CI, 1.41À4.35) in the npo (fasting) group (1 trial); in the comparison of npo vs TPN, ICU LOS was significantly shorter for the npo (fasting) group WMD ¼ À10.5 days (95% CI, À15.74 to À5.24 days) (1 trial) ( Table 9) .
Recommendations for future clinical trials on the topic. In predicted severe and proven necrotizing AP, there is a need to more precisely define the timing of early vs delayed feeding (by oral, NG, or NJ routes) and to investigate whether timing of feeding impacts major outcomes. The value of nutritional additives in enteral nutrition should also be assessed, for example, immuno-nutrition 55 (eg, glutamine) and fiber-enriched formulations. Effect of the route of enteral feeding on the primary outcomes of death, PMOF, PSOF, MOF of unclear duration, single organ failure of unclear duration, and infected (peri) pancreatic necrosis, as well as total infected pancreatic necrosis and hospital LOS.
Quality of evidence: Low Background information. See background information to the inter-related PICO question 4, addressing early vs delayed feeding mentioned previously.
Results from the current systematic review. From 547 citations, we identified 3 RCTs that compared NJ compared to NG in SAP (Table 12 ). Mortality was not significantly different between the 2 groups (OR, 1.01; 95% CI, 0.44À2.30). Similarly, none of the other outcomes were significantly different for NJ compared to NG. Some methodologic problems exist in these studies, for example, NJ feeding was actually nasoduodenal in 1 study and mortality was higher than usual in the SAP group. 60 Significant weaknesses of these analyses are that each study used different criteria to define SAP, and data for all major outcomes except death were derived from only 1 small study each (Table 13) .
Recommendations for future clinical trials on the topic. In predicted severe or proven necrotizing AP, there is a need to more precisely define the optimal route of feeding patients (oral vs NG vs NJ routes) and to determine whether the rate, total calories, and composition of feeds impacts clinically important outcomes. Standard when treating physician considered the patient to be pain free and ileus subsided CT, computed tomography; ED, emergency department; EN, enteral nutrition; GI, gastrointestinal; ICU, intensive care unit; IVF, intravenous fluid; KUP, radiographic study of the kidneys, ureter, and bladder. OF, organ failure; ULN, upper limit of normal; US, ultrasound; WBC, white blood cell. a Intervention arm. b Control arm. Blinding of participants and personnel and Blinding of outcome assessment was high, it was not judged to have an impact on the outcomes for this PICO. Optimal information size not reached, all trials except one were double zero event.
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AGA SECTION 62, [64] [65] [66] According to a recent systematic review, readmission rates averaged 18% at 6 weeks after an index stay for biliary pancreatitis in the subset with gallbladder in situ. 67 In those who are unsuitable surgical candidates, biliary sphincterotomy reduces the risk of developing recurrent gallstone pancreatitis, but not other biliary complications. [67] [68] [69] [70] The timing of cholecystectomy for gallstone pancreatitis is controversial (and is the focus of 2 RCTs, 71, 72 but outside the focus of this PICO). In mild AP, older medical and surgical guidelines recommend cholecystectomy at variable times ranging from the index hospitalization to several weeks after hospital discharge. Clinical practice has similar variability, which reflects factors that support or oppose early cholecystectomy, both knowledge of risks of recurrent biliary complications without performing cholecystectomy, but also challenges with surgical scheduling and concerns about data quality and the safety and operative risks in the setting of active inflammation and potentially altered anatomy. Recent guidelines 8, 9 and a recent systematic review 67 recommend same-admission cholecystectomy for mild, interstitial pancreatitis, and provide additional recommendations for more severe cases. In mild AP attributed to gallstones, cholecystectomy is recommended during the index hospitalization (moderate quality of evidence). In those with moderate to severe acute gallstone pancreatitis having (peri) pancreatic collections, surgery should be postponed until "active inflammation subsides and fluid collections resolve or stabilize" 73 after approximately 6 weeks. 9 Delaying cholecystectomy in moderate to severe disease appears to reduce morbidity, 67 including infected collections 74 and mortality. 71 These latter observations are further supported by recent retrospective observations that inadvertent underestimation of severity of acute gallstone pancreatitis is associated with increased complications in those undergoing cholecystectomy during the index hospitalization. 75 Results of the current systematic review. From an initial 120 citations, we identified only 1 RCT (n ¼ 264) that addressed the role of same admission vs delayed cholecystectomy in patients with mild acute gallstone pancreatitis (Table 14) . Same-admission cholecystectomy (Table 15) .
Recommendations for future clinical trials on the topic. Future studies should further clarify the optimal timing of laparoscopic cholecystectomy during the index hospitalization for mild AP in the modern era, and also determine the optimal timing of cholecystectomy for severe necrotizing pancreatitis. Additional issues that require study include whether to routinely screen for local (peri) pancreatic collections using predictive tools or crosssectional imaging to triage patients to early vs delayed surgery, the role of endoscopic sphincterotomy as a bridge to cholecystectomy in patients with more severe pancreatitis, 76, 77 and the elaboration of predictive tools to exclude patients with moderately severe or severe pancreatitis who might require a delay in cholecystectomy. Effect of alcohol counseling on total hospital admissions, recurrent pancreatitis (second attack), definite recurrent pancreatitis, likely recurrent pancreatitis, and 2 or more recurrent attacks pancreatitis, as well as alcohol abstinence, alcohol consumption in grams per 2 months, Short Alcohol Dependence Data questionnaire (scale, 0L45), and laboratory markers of alcohol use.
Quality of evidence: Moderate Background information. Alcohol remains one of the more common causes of AP. In most analyses, some degree of chronic pancreatic injury is present at the time of the first clinical attack, suggesting a prolonged period of subclinical injury before presentation with AP. Pancreatitis does not appear to occur from isolated binge drinking, 78 and generally requires several years of ongoing substantial alcohol use. Of importance, <5% of patients with significant alcohol use will develop pancreatitis. 79 These data suggest that additional cofactors are necessary to confer susceptibility to pancreatitis associated with alcohol, including risk factors (eg, smoking, genetic susceptibility, dietary factors, heredity, and alcohol type) and protective factors (eg, caffeinated coffee). Once pancreatitis develops, it can be severe, and chronic pre-existing alcohol use is a risk factor for pancreatic necrosis (regardless of the primary cause) and higher mortality from the initial episode of AP. A recent report suggested that recurrent attacks occurred in 24% after an attack of acute alcoholic pancreatitis and chronic pancreatitis developed in 16% of them. 80 Alcohol and smoking were independently associated with progression to chronic pancreatitis and had additive risk. Surprisingly, smoking, but not alcohol, was associated with risk of recurrences. Abstinence from alcohol (and also tobacco) after the first attack is recommended to reduce the risk of diseases related to these toxins (ie, cirrhosis and lung cancer), reduce the risk of secondary pancreatic malignancy, and reduce the risk of subsequent episodes of pancreatitis. Abstinence also slows or decreases the risk of evolution to advanced chronic pancreatitis, particularly pancreatic function, 81 while effects on reducing pain are inconsistent. 82 There are no trials comparing specific efforts at smoking cessation and relapses of AP, although multiple lines of evidence support the benefit of achieving smoking cessation in non-pancreatic diseases, but such intervention is not addressed by a PICO in this technical review.
Results from the current systematic review. From 63 citations, we identified only 1 RCT that addressed the role of alcohol counseling on recurrent bouts of AP (Table 16 ). The included patients had a clear alcohol history and had undergone a first attack of AP with the exclusion of other possible etiologies. Comparing similar interventions of alcohol counseling as a sole session at the initial hospitalization vs every 6 months for 2 years in a gastrointestinal clinic setting, a strong trend favored the repeated intervention for the outcome of total hospital admission rates (OR, 0.38; 95% CI, 0.14À1.00), with nonsignificant differences noted for the other outcomes of a second attack of pancreatitis (OR, 0.34; 95% CI, 0.11À1.03), definite recurrent pancreatitis (OR, 0.34; 95% CI, 0.11À1.03), or 2 or more recurrent attacks of pancreatitis (OR, 0.56; 95% CI, 0.16À2.03). Additional outcomes were not assessed in the trial (Table 17 ). An important limitation of this analysis is, of course, the paucity of randomized trials available in the literature in the context of patients with AP. Additional pertinent data from a systematic review in a different patient population from which the information may be applied to patients with AP. A Cochrane review of alcohol-reduction strategies was also considered; while the trials this systematic review refers to were not carried out in the context of patients presenting with AP, the effect of an intervention strategy was assessed in a large number of studies (22 RCTs) and evaluated outcomes in >5800 patients. 83 Patients who received a brief intervention had a significant reduction in alcohol consumption compared with controls after 1 year (À38 g/ wk; 95% CI À54 to À23 g/wk), although substantial heterogeneity between trials was noted and the benefit of brief intervention was statistically significant in men but not in women. Extended intervention was associated with a nonsignificantly increased reduction in alcohol consumption compared with brief intervention. In the absence of any dose threshold linking alcohol intake to AP and its recurrence, and in the absence of any significant untoward effects related to the proposed intervention, this evidence was applied to the PICO under consideration, while the level of evidence was downgraded for indirectness and chosen outcomes.
Recommendations for future clinical trials on the topic. Future studies should focus on patients with a first attack of alcoholic pancreatitis, and should include both separate and combined efforts at alcohol and tobacco cessation. Outcomes of interest could include recurrent attacks, progression to chronic pancreatitis, need for further intervention for necrosis, quality of life, health care utilization and cost, development of subsequent pancreatic cancer, and mortality. 8, 9 for managing AP recommend that clinicians predict the severity of AP during the early phase of the condition. The goals of using these predictive tools are to help identify sicker patients, allowing patient triage to the appropriate level of care (eg, intensive care unit) or to treatments appropriate for sicker individuals (enteral feeding), but also to identify those with milder disease, who might be candidates for earlier hospital discharge. Although in the absence of any specific therapy that can be applied to those predicted to have a severe or moderately severe course, the clinical utility of predictive tools can be questioned. A multitude of predictive tools are available for use, including clinical scoring systems (eg, APACHE II, GlasgowImrie score, and Japanese severity score), patient characteristics (eg, body mass index, age), single or multiple laboratory markers (BUN, creatinine, CRP), some of which have been used dynamically to assess the patient's response to care over time (eg, SIRS and BUN). A recent report actually suggested that current scoring systems have reached their limit to predict persistent organ failure with no good positive predictive value and future research should include novel approaches. 84 In another recent systematic review, no single tool is favored and most tools have only moderate predictive value for predicting development of persistent organ failure or infected pancreatic necrosis. 85 For this reason, there is general consensus from guidelines and among experts to utilize expert clinical judgment and a variety of predictive tools to best estimate predicted severity. An initial 1260 citations were retrieved from the systematic literature search and 839 full-text articles were reviewed. What is lacking in the literature are specific studies focused on whether utilizing a risk severity assessment tool during the early management of AP impacts outcomes, which would match the aim of the systematic review of identifying interventions or treatments that impact outcomes, and more specifically the a prioriÀset objective for this PICO. A single study that comes closest to addressing this question focused on whether use of tools to predict severity (SIRS, BISAP [Bedside Index for Severity in Acute Pancreatitis], or transient organ failure) coupled with a structured management approach would impact outcomes. 86 Whereas the structured management of AP compared to usual care in historical controls has been shown to be associated with a significant reduction in hospital LOS without affecting other major outcomes (eg, persistent organ failure or pancreatic necrosis), it is difficult to tease apart the individual contribution of such predictors on any clinically important outcome. Moreover, all predictors have tried to prognosticate SAP and the only study that attempted to predict the moderately severe type of AP found it impossible to distinguish this entity from SAP. 87 Results of the current systematic review. All of the reasons mentioned, and the absence of any observational study or RCT on the clinical impact of using severity prediction tools, prevented us from identifying any gradable evidence.
Recommendations for future clinical trials on the topic. There is a need to identify predictive markers or tools that are accurate in prognosticating both moderately severe and SAP during the initial 24À72 hours. In addition, measuring clinical outcomes in groups with and without the use of such tools is also required, but clinically pertinent only if a drug or other specific therapy is available to treat AP.
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